Franklin Resources Inc. Acquires 94,179 Shares of Pfizer Inc. $PFE

Franklin Resources Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 0.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 25,164,327 shares of the biopharmaceutical company’s stock after buying an additional 94,179 shares during the period. Franklin Resources Inc.’s holdings in Pfizer were worth $626,592,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Erste Asset Management GmbH raised its holdings in Pfizer by 302.5% during the 4th quarter. Erste Asset Management GmbH now owns 663,819 shares of the biopharmaceutical company’s stock worth $16,595,000 after purchasing an additional 498,898 shares during the last quarter. Brandywine Global Investment Management LLC raised its holdings in Pfizer by 77.8% during the 4th quarter. Brandywine Global Investment Management LLC now owns 2,857,645 shares of the biopharmaceutical company’s stock worth $71,155,000 after purchasing an additional 1,250,255 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Pfizer by 47.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 2,621,063 shares of the biopharmaceutical company’s stock worth $65,264,000 after purchasing an additional 838,851 shares during the last quarter. Hilton Head Capital Partners LLC bought a new position in Pfizer during the 4th quarter worth approximately $337,000. Finally, ING Groep NV raised its holdings in Pfizer by 9.7% during the 4th quarter. ING Groep NV now owns 846,883 shares of the biopharmaceutical company’s stock worth $21,087,000 after purchasing an additional 74,769 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported encouraging Phase 2b data for its once-monthly obesity drug, showing about 15.9% to 16% weight loss, reinforcing hopes that the company could become a more meaningful player in the fast-growing weight-loss market. Pfizer’s obesity drug shows 16% weight loss in phase 2b study
• Positive Sentiment: The U.S. FDA expanded approval of Pfizer’s HYMPAVZI for additional hemophilia A and B patient groups, including pediatric patients, which should widen the drug’s addressable market and support future sales growth. U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
• Positive Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside in PFE, reflecting rising near-term optimism around the company’s pipeline news.
• Neutral Sentiment: Pfizer also presented at Goldman Sachs’ Global Healthcare Conference, but no major new strategic update was highlighted in the available summary. Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Competition in obesity drugs remains intense, with another company reporting strong weight-loss results, reminding investors that Pfizer will need to keep delivering to compete in this high-profile market. Sciwind Reports 12.8% Weight Loss As Global Expansion Talks Deepen

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Barclays initiated coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. Morgan Stanley raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Price Performance

PFE opened at $25.66 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a market capitalization of $146.22 billion, a price-to-earnings ratio of 19.58 and a beta of 0.34. The firm’s fifty day moving average price is $26.59 and its two-hundred day moving average price is $26.30. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.